Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive
research. Nowadays, only symptomatic treatments exist for this disease, all trying to …

Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …

Alzheimer's disease (AD) is a neurodegenerative old age disease that is complex,
multifactorial, unalterable, and progressive in nature. The currently approved therapy …

The management of the central nervous system (CNS) disorders is challenging, due to the
need of drugs to cross the blood‒brain barrier (BBB) and reach the brain. Among the …

Abstract According to the Alzheimer Association Report (2017), Alzheimer's disease (AD) is
the 6th primary cause of death in the USA, which affects nearly 5.5 million people. In the …

Nanostructured lipid carriers (NLC), comprises of a blend of solid and liquid lipids which
results in a partially crystallized lipid system and imparts many advantages over solid lipid …

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

Despite all scientific efforts and many protracted and expensive clinical trials, no new drug
has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed …

CNS disorders are on the rise despite advancements in our understanding of their
pathophysiological mechanisms. A major hurdle to the treatment of these disorders is the …

Since the application of chitosan magnetic cationic microspheres in brain drug delivery by
Gallo in 1993, chitosan has been extensively studied in brain drug delivery. As the only …